Peptide questions · TB-500

TB-500 side effects: what studies and users report

Reviewed Evidence: EmergingPublished by PepVault

The side effects most commonly reported for TB-500 are injection site reaction, fatigue and nausea, among 5 the library lists; the library’s evidence on it includes controlled trials in people.

Its safety note opens: Published human safety data is sparse and comes almost entirely from topical/IV thymosin beta-4 (Tβ4) wound-healing trials — not injected TB-500 — where no serious drug-related adverse events were reported (tolerability generally acceptable, effects mild and transient).

What is commonly reported with TB-500

  • Injection site reaction
  • Fatigue
  • Nausea
  • Headache
  • Lethargy

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other healing & recovery compounds the library lists it for
EffectAlso listed for (of 18)
Injection site reaction6: GHK-Cu, AOD-9604, Thymosin Alpha-1, Thymosin Beta-4 and 2 more
Fatigue5: Thymosin Alpha-1, Thymosin Beta-4, ARA-290, Abaloparatide and 1 more
Nausea6: BPC-157, AOD-9604, Larazotide, ARA-290 and 2 more
Headache6: Thymosin Beta-4, Linaclotide, VIP, ARA-290 and 2 more
LethargyNone: listed for TB-500 alone
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track TB-500 in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which TB-500 side effects the healing & recovery group shares

Across the 19 healing & recovery compounds in the library, the effects listed most often are headache (7 of 19), injection site reaction (7 of 19), nausea (7 of 19) and fatigue (6 of 19). TB-500 shares 4 of its 5 listed effects with at least one other healing & recovery compound; lethargy is listed for TB-500 alone.

What the TB-500 safety notes say

The library’s safety note

Published human safety data is sparse and comes almost entirely from topical/IV thymosin beta-4 (Tβ4) wound-healing trials — not injected TB-500 — where no serious drug-related adverse events were reported (tolerability generally acceptable, effects mild and transient). FDA (April 2026) says it has found no human exposure data for TB-500 and flags a possible risk of immune reactions to compounded versions. Community-reported effects include transient injection-site irritation, head-rush, mild headache, and lethargy. Because Tβ4 promotes angiogenesis and has a documented role in cell migration, a theoretical malignancy concern is noted in the literature; discuss with your clinician.

The library’s interaction note

No published interaction data exists for TB-500 with SSRIs, anticoagulants, antidiabetics, or thyroid medication. Mechanistically it shares no obvious pathway with these classes, but the absence of study means caution is warranted rather than reassurance. When stacked with other healing peptides (e.g. BPC-157) the combined proangiogenic effect is a theoretical consideration worth raising with a clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the TB-500 reports come from

The library rates the evidence on TB-500 as emerging: mostly preclinical, with limited human data.

Of the library’s 7 research notes on TB-500, 1 rest on clinical data, 3 on animal studies and 3 on community reports.

Our 9 study pages on TB-500: 1 animal study (rats), 2 randomized trials, 4 animal studies (mice), 1 cell study (human brain organoids) and 1 cell study (hCMEC/D3 human cerebral endothelial cells).

So TB-500 has controlled trials in people to set its listed effects against.

What our TB-500 study pages report on safety

TB-500 on venous ulcers: safety comparable to placebo in Phase 2

Randomized trial, human, 2010: At every dose tested, the safety of thymosin beta 4 was judged acceptable and similar to placebo. An early human trial found thymosin beta 4 on venous ulcers had safety comparable to placebo, with early signs that the 0.03% dose might speed healing.

Questions people ask

What are the side effects of TB-500?

The side effects most commonly reported for TB-500 are injection site reaction, fatigue and nausea, among 5 the library lists; the library’s evidence on it includes controlled trials in people.

Do TB-500’s side effects come from human studies?

The library rates the evidence on TB-500 as emerging, and the library’s evidence on it includes controlled trials in people.

Which TB-500 side effects are its own?

Among the healing & recovery compounds, the library lists lethargy for TB-500 alone.

Does TB-500 interact with other medicines?

The library’s interaction note on TB-500 begins: No published interaction data exists for TB-500 with SSRIs, anticoagulants, antidiabetics, or thyroid medication.

More on TB-500

Track it in the app

PepVault for iPhone

Track TB-500 in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo